Shots: The P-I study involved assessing of [Fam-] trastuzumab deruxtecan (5.4, 6.4 mg/kg) in 46 patients with heavily pretreated HER2 low expressing metastatic breast cancer P-I study results: ORR (44.2 […]readmore
![Daiichi Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for HER2 Low Expressing Metastatic Breast Cancer](https://pharmashots.in/wp-content/uploads/2018/12/Daiichi.jpg)
Tags : Daiichi
Shots: Medical Developments International (MVP) to receive up to $32.5M (AUD $45.8M) as total deal value plus $15M upfront and additional sales-based milestones payments MVP will fund the regulatory process […]readmore